PharmAust Expands Site Recruitment for Phase II Pet Dog Cancer Trial
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.
The company’s lead drug candidate is Monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer.
MPL has been evaluated in Phase 1 clinical trials in both humans and dogs. It was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials. MPL is a repurposed drug that’s already approved for veterinary use by Elanco Animal Health.
With the additional participating sites and an associated advertising campaign, PharmAust now expects the pace of recruitment of canine patients to be increased.
In conjunction with the trial manager, U-Vet in Werribee, and through the University of Melbourne’s Department of Veterinary Clinical Sciences, PharmAust has now also contracted the University Veterinary Teaching Hospital at the University of Sydney (UVTHS) as well as the West Australian Veterinary Emergency and Specialists (WAVES) in Perth.
The UVTHS site will be run by Dr Peter Bennett and the WAVES site will be run by Dr Sue Bennett (no relation). Dr Peter Bennett is one of Australia’s leading cancer clinical trial specialists and both sites are highly acknowledged and recognised for their work in treating veterinary cancer.
With the addition of these two sites, PharmAust now has central referral sites within Victoria, New South Wales (two including the previously announced Animal Referral Hospital in Homebush, Sydney) and Western Australia.
The company anticipate this national network to facilitate and expedite the generation of meaningful and successful outcomes for this trial.
In further supporting this network and expediting recruitment, PharmAust has also engaged a pet journalist and has commenced an aggressive marketing awareness campaign to vets and pet owners.
PharmAust’s Chief Scientific Officer Dr Richard Mollard stated: “PharmAust is pleased and excited to have the support and involvement of Dr Peter Bennett and Dr Sue Bennett. Having the participation of such highly accredited veterinarians and hospitals is a tribute to the diligent preclinical and clinical work PharmAust has executed preparing monepantel for re-entry into the clinic for this pivotal trial. PharmAust is looking forward to reporting meaningful and successful outcomes to the market.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
